Expert Q&A on Recent Developments with Orange Book-Listed and Biologic Patent Challenges at the PTAB | Practical Law

Expert Q&A on Recent Developments with Orange Book-Listed and Biologic Patent Challenges at the PTAB | Practical Law

An expert Q&A with Gregory A. Morris of Honigman Miller Schwartz and Cohn LLP on recent developments in inter partes review (IPR) challenges of Orange Book-listed and biologic patents before the Patent Trial and Appeal Board (PTAB). The Q&A discusses the success rates of these challenges to date, recent Supreme Court and USPTO guidance on relevant PTAB procedure, estoppel and other considerations across the IPR-district court interface, and the role of objective indicia of non-obviousness in pharmaceutical patent IPR challenges.

Expert Q&A on Recent Developments with Orange Book-Listed and Biologic Patent Challenges at the PTAB

by Practical Law Intellectual Property & Technology
Law stated as of 02 Jul 2018 • USA (National/Federal)
An expert Q&A with Gregory A. Morris of Honigman Miller Schwartz and Cohn LLP on recent developments in inter partes review (IPR) challenges of Orange Book-listed and biologic patents before the Patent Trial and Appeal Board (PTAB). The Q&A discusses the success rates of these challenges to date, recent Supreme Court and USPTO guidance on relevant PTAB procedure, estoppel and other considerations across the IPR-district court interface, and the role of objective indicia of non-obviousness in pharmaceutical patent IPR challenges.